ClinicalTrials.gg
RecruitingNCT04254419Updated May 13, 2025

Phase 1 Study of Locoregional Injections of Ex Vivo Expanded Natural Killer Cells

A Phase 1 interventional study of NK cells in High Grade Glioma, sponsored by Nationwide Children's Hospital. Recruiting at 1 site in United States. Open to participants aged 12 Months to 39 Years. Per ClinicalTrials.gov, last updated 2025-05-13.

Sponsored by Nationwide Children's Hospital · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
12 Months to 39 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Glioma by Nationwide Children's Hospital — 9 open to participants now, 11 under way, none of them phase 3. Glioma · Nationwide Children's Hospital.

Planned enrollment
7th of 10
18 · median 62
Started
2025
with 2 others
Phase 1
4 of 11
2 open now
Primary completion
2030-12
later than 9 of 10 live
Registered
2nd of 11
by date

Among the 11 studies in Glioma by Nationwide Children's Hospital, this one is the 7th largest by planned enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2025, is one of 4 in phase 1, reaches primary completion later than 9 of the 10 other live ones, and was the 2nd registered.

Glioma

1,456 studies on the registry are indexed under Glioma; 351 are open to participants now.

Browse Glioma studies →

Open to participants now

9 of the 11 studies in Glioma by Nationwide Children's Hospital are open now, in 7 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 267 Glioma studies recruiting now, 165 (62%) set no upper age limit and 57 (21%) stop at 75 or younger; 63 take children under 18; 15 take healthy volunteers.

This study: 12 Months to 39 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Glioma by Nationwide Children's Hospital, or all of them as a file.
02

Study summary

Each patient will receive up to 12 cycles of TGFβi NK cell infusions. Each cycle will be of 4 weeks duration. During the first 3 weeks, TGFβi NK cells will be infused once weekly. The 4th week will be a rest week. TGFβi NK cell infusions should be delivered at least 3 days apart (e.g., Friday of Week 1 and Monday of Week 2). Dose will be escalated in an inter-patient stepwise fashion consisting of 3 dose levels.

Read the detailed description

A cycle is 28 days (4 weeks) consisting of weekly infusions of UD TGFβi NK cells via Ommaya or a programable ventriculoperitoneal (VP) shunt for three weeks followed by one week of rest. The dose-limiting toxicity (DLT) period is the first 28 days (4 weeks). A DLT is defined as any event that is at least possibly attributable to the TGFβi NK cell product and that occurs from the time of initial NK cell infusion through the end of the first cycle (28 days). Patients with stable or improved disease will receive up to 12 cycles of TGFβi NK cell infusions.

03

Conditions studied

  • High Grade Glioma

Browse trials for

04

Who can participate

Ages eligible
12 Months to 39 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Diagnosis:

Recurrent, , or progressive malignant CNS tumor

  • Patients with a confirmed diagnosis of a CNS tumor that is recurrent, progressive, or refractory with the exception of diffuse midline gliomas (DMG) or Diffuse Intrinsic Pontine Gliomas (DIPG). All tumors must have histologic verification at either the time of diagnosis or recurrence.
  • Patients should be deemed candidate for placement of an Ommaya reservoir placed intra-cavitary/intra-tumoral or a programable VP shunt.
  • Measurable residual tumor after surgery is not required for study entry.
  • Resection cavity needs to be at least 2 cm x 2 cm in two dimensions on imaging for patients deemed as candidates for an intratumoral infusion via an Ommaya reservoir.

    • Performance score: Lansky score of 50 or greater if ≤ 16 years of age or a score of 50 or greater if > 16 years of age. Participants who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
    • Adequate bone marrow function, without transfusion or growth factors within 21 days of NK cell administration.
    • Adequate liver function
    • Adequate Renal Function
    • /international normalized ratio
    • Patients of must agree to use adequate
    • Adequate neurologic function defined

Prior Therapy:

  • Chemotherapy

    • All patients must have received their last dose of known myelosuppressive anticancer therapy at least 21 days prior to enrollment or at least 42 days of nitrosourea.
    • For patients who have received prior bevacizumab, at least 6 weeks must have elapsed prior to enrollment.
  • Biologic or agent (anti-neoplastic, non-myelosuppressive):

    • Patient must have recovered from any acute toxicity potentially related to the agent and received their last dose of the investigational or biologic agent ≥ 14 days prior to study enrollment.
    • For agents with known adverse events occurring beyond 14 days after administration, this period must be extended beyond the time during which adverse events are known to occur.
    • At least 12 weeks since the completion of any immunotherapies or cell therapies.
  • Radiation Therapy

    • Focal radiation therapy > 6 weeks prior to enrollment.
    • Craniospinal irradiation >12 weeks.
  • Stem Cell Transplant.

Patient must be:

  • ≥ 6 months since stem cell transplant prior to enrollment with no evidence of active graft vs. host disease.
  • ≥ 3 months since autologous stem cell transplant prior to enrollment.

    • Growth Factors
  • Patients must be off all colony- forming growth factor(s) for at least 1 week prior to enrollment (e.g., filgrastim, sargramostim or erythropoietin).
  • 2 weeks must have elapsed if patients received long-acting formulations.

  • Patients who are receiving dexamethasone must be on a stable or decreasing dose for at least 1 week prior to enrollment.

Exclusion criteria

Exclusion Criteria:

  • Patients with intra- or extra- or multi-focal disease.
  • Patients with diffuse midline gliomas or Diffuse Intrinsic Pontine Gliomas (primary or recurrent).
  • Pregnant or lactating patients.
  • Participants who are receiving any other agents.
  • Evidence of active uncontrolled infection or unstable or severe intercurrent medical conditions.
  • Any medical condition that precludes surgery.
  • Patients with a known disorder that affects their immune system, such as (HIV), or an auto- immune disorder requiring systemic cytotoxic or therapy are not eligible.
  • Evidence of bleeding diathesis or use of anticoagulant medication or any medication which may increase the risk of bleeding.
  • Patients who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study are not eligible.
  • History or current diagnosis of any medical or psychological condition that in the Investigator's opinion, might interfere with the subject's ability to participate
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    NK cell infusion

    The TGFβi NK cell product on this trial will be manufactured in the Cell Based Therapy (CBT) Core facility at Nationwide Children's Hospital. Donors have been identified with specific universal-donor NK cell characteristics. The NK cells are collected from these donors via apheresis and then undergo CD3 depletion followed by a 2-week expansion. TGFβi NK cells are then generated by weekly stimulation with feeder cells and cultured in IL-2 and TGFβ. After 2 weeks, the TGFβi NK cells are washed and cryopreserved for future use. The expanded donor NK cell product will be manufactured prior to subject enrollment. Patients will receive 3 cycles of NK cell infusions over 12 weeks. Each cycle will consist of three weekly injections followed by a rest week (week 4). If patients have stable or improved disease and additional doses are available, patients may continue to receive therapy for a total of 12 cycles.

    Biological: NK cells

Interventions

  • BiologicalNatural Killer CellStudies of Natural Killer CellNatural Killer Cell pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The universal donor TGFβi NK cells will be cryopreserved until they are delivered bedside for infusion. The trained staff will thaw the product by the bedside. The administration of the cells will be done via an Ommaya intra-cavitary/a programable ventriculoperitoneal (VP) shunt. Once the infusion is ready for administration patients will be admitted to the infusion unit for monitoring. NK cells will be administered through the Ommaya/VP shunt in approximately 3 milliliters over approximately 2-5 minutes; followed by 1.5-2 milliliter preservative-free normal saline flush over approximately 1 minute.

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose or Recommended Phase 2 Dose (RP2D)

    To determine the maximum tolerated dose (MTD) and/or the RP2D of UD TGFβi NK cells that have been propagated ex vivo with genetically modified feeder cells and administered using an Ommaya reservoir (into tumor cavity) or a programable ventriculoperitoneal shunt (intraventricular).

    Time frame: 36 months

  2. Maximum tolerated dose

    To establish the maximum tolerated dose (MTD) of autologous natural killer cells that have been propagated ex vivo with genetically-modified feeder cells and administered intra-tumoral via Ommaya reservoir in patients with recurrent high-grade glioma. MTD will be the maximum dose at which fewer than one-third of patients experience a dose-limiting toxicity during cycle 1 of therapy

    Time frame: 36 months

Secondary outcomes

  1. Define tumor activity in children

    To preliminarily define the antitumor activity in children with recurrent, refractory, or progressive primary malignant CNS tumors with the exception of diffuse midline gliomas and or diffuse intrinsic pontine glioma as measured by objective response rate (ORR) of UD TGFβi NK cells within the confines of a Phase I study.

    Time frame: 6 months

Other outcomes

  1. NK cell antitumor activity

    To assess the antitumor activity based on imaging and cytology of autologous NK cell administration directly into the tumor or the resection cavity.

    Time frame: 36 months

  2. Assessment of the immuno-phenotype of expanded NK cells for high-grade glioma patients

    To determine the persistence, immuno-phenotype and function of adoptively transferred expanded TGFβi NK cells and correlate the findings with the overall response.

    Time frame: 36 months

  3. Assessment of health-related quality-of-life of patients using patient reported outcomes measurement information system (PROMIS)

    To assess health-related quality-of-life of patients by parent report, and when possible patient report using PROMIS.

    Time frame: 36 months

  4. Assessment of the immune signature based profile

    To determine the gene expression-based immune profile of each patient's tumor (e.g., RNA-seq or NanoString).

    Time frame: 36 months

  5. Changes of the T-cell Receptor (TCR) Repertoires in Tumor Tissue before and after NK Cell Treatment

    The aim is to compare the mRNA expression of specific immune genes before and after NK cell treatment. By analyzing RNA from tumor tissue, we will identify and quantify immune cells in each patient's tumor. These profiles will be linked to treatment outcomes, helping understand response or non-response. For patients whose disease progresses, the goal is to study changes in their immune cells through RNA analysis.

    Time frame: 36 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Dec 2030, 69 months after the start.

Of 166 non-industry phase 1 interventional studies under Glioma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 87. This study's planned 69 months is above that.

Counting every sponsor, half of 213 studies reached it within 59 months; a quarter within 36 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2020
First posted
Feb 5, 2020
StartActual
Mar 4, 2025
Primary completionEst.
Dec 31, 2030
CompletionEst.
Oct 2031
Last update
May 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04254419
Responsible party
Sponsor
First posted
Feb 5, 2020
Start date
Mar 4, 2025
Primary completion
Dec 31, 2030 (estimated)
Completion
Oct 2031 (estimated)
Last update
May 13, 2025

Study contacts

Clelie Peck
Contact
Clelie.Peck@nationwidechildrens.org
614-722-5634
Lauren Rayman
Contact
lauren.rayman2@nationwidechildrens.org
614-722-3729
Sara Khan, MD
principal investigator · Nationwide Children's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Natural Killer Cell

Start the discussion